KB-9558 / Kronos Bio - LARVOL DELTA

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right (The Manila Times) - "Kronos Bio, Inc...announced that it has entered into a definitive merger agreement (the 'Merger Agreement') with Concentra Biosciences, LLC ('Concentra'), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock ('Kronos Bio Common Stock'), plus one non-tradeable contingent value right ('CVR'), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-9558 and KB-7898 that occurs within 2 years following closing; (ii) 100% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-0742, lanraplenib and entospletinib that occurs prior to closing..."

M&A • Breast Cancer • Graft versus Host Disease • Lupus • Multiple Myeloma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Ovarian Cancer • Prostate Cancer • Rheumatoid Arthritis

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives (GlobeNewswire) - "Kronos Bio...explores options for the Company and its remaining internally developed preclinical assets, one of which could include partnering the two p300 lysine acetyltransferase (KAT) inhibitor programs: an oncology candidate, KB-9558, for multiple myeloma and HPV-driven cancers expected to be IND-ready by the end of 2024..."

IND • Multiple Myeloma

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma (GlobeNewswire) - "Kronos Bio is exploring the utility of its p300 KAT inhibitor, KB-9558, for multiple myeloma as well as HPV-driven tumors. In the presentation of preclinical data from the multiple myeloma program, the authors show that a context-specific and strong relationship exists between transcription factor interferon regulatory factor 4 (IRF4) and p300, a protein that impacts genes that are linked to cancer cell proliferation and survival. Furthermore, IRF4 and p300 display a preferential protein-protein interaction via a statistically similar network of interactors which was not evident with other transcription factors tested."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

Oncogenic human papillomavirus hijacks p300 to drive viral transcription, creating a therapeutic vulnerability that can be exploited with selective p300/CBP catalytic inhibitors (EORTC-NCI-AACR 2024) - "We identified oncogenic viral transcription as a therapeutic vulnerability in HPV+ tumors, exploitable by targeting p300. We show that at efficacious exposures, p300 KAT inhibition is highly selective against E6 and E7 production, and that their loss drives anti-tumor effects. Kronos Bio is currently developing KB-9558, a p300 KAT inhibitor, as an oncology clinical candidate."

Cervical Cancer • Head and Neck Cancer • Oncology • Solid Tumor

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors (GlobeNewswire) - "In the presentation, the authors show that the HPV genome preferentially integrates into transcriptionally active regions in the human genome where it becomes dependent on p300 to drive expression of its E6 and E7 oncogenes. It is widely recognized that elevated transcription of HPV E6 and E7 genes promotes degradation of tumor suppressors p53 and Rb. Importantly, inhibition of p300 KAT activity was highly selective in repressing the transcription of E6 and E7, which in turn led to restoration of the p53 and Rb pathways and drove anti-tumor effects through apoptosis and inhibition of uncontrolled tumor cell growth."

Preclinical • Oncology • Solid Tumor

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors (GlobeNewswire) - "Kronos Bio...announced that it will present preclinical data from its p300 KAT inhibitor program for human papillomavirus (HPV)-driven tumors at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics....Kronos Bio is exploring the utility of its p300 KAT inhibitor, KB-9558, for HPV-driven tumors. In the presentation, the authors will show that the oncogenic HPV-16 virus hijacks the host transcriptional cofactor p300 in order to drive expression of the virally encoded oncogenes E6 and E7. Inhibition of p300 KAT activity achieved anti-tumor effects by downregulating E6 and E7 which in turn leads to reactivation of p53, a known tumor suppressor."

Preclinical • Oncology

Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update (GlobeNewswire) - "KB-9558, a p300 lysine acetyltransferase (KAT) inhibitor for oncology indications:...Development of KB-9558 remains on track to complete IND-enabling studies in 2024 and the Company expects to enroll the first patient in a dose escalation study in relapsed/refractory multiple myeloma in the first half of 2025. Today the Company announced an additional opportunity for the potential use of KB-9558 in HPV-driven tumors. Data supporting p300 KAT inhibition in HPV-driven tumors will be presented later this year."

New trial • Preclinical • Multiple Myeloma • Solid Tumor

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results (GlobeNewswire) - "KB-9558 is the second development candidate to emerge from Kronos Bio’s product engine...The Company plans to present data on KB-9558 at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California, including how targeting p300’s enzymatic KAT domain can selectively downregulate IRF4....Pending completion of IND-enabling studies in 2024, the Company intends to initiate a first-in-human trial in relapsed or refractory multiple myeloma in the first half of 2025."

New trial • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate (GlobeNewswire) - "After a review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the Company has decided not to proceed to phase 2. The Company is open to further development of lanraplenib, a SYK inhibitor, with a partner. Kronos Bio also announced the designation of a new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 transcription regulatory network (TRN). IRF4 is a key driver in multiple myeloma. KB-9558...is currently in IND-enabling studies, which are expected to be completed in the fourth quarter of 2024."

New molecule • Trial status • Acute Myelogenous Leukemia • Multiple Myeloma